BRD2 and colorectal carcinoma: Previous studies on metabolic alterations of CRC have predominantly focused on analyzing tumor tissue and paired NAT.[29] However, recent findings suggest that NAT represents a distinct state between normal and tumor tissues, which may exhibit unique metabolic alterations.[7, 28, 30, 31] A targeted liquid chromatography‐mass spectrometry (LC‐MS)‐based metabolomics method developed previously was applied in this study to capture the metabolic changes during UC‐CRC progression.